PremiumCompany AnnouncementsSAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and Growth Hold Rating for SAGE Therapeutics: Inventory Challenges and Strategic Prospects SAGE Therapeutics’ Earnings Call: ZURZUVAE’s Success Amid Challenges PremiumRatingsSAGE Therapeutics: Hold Rating Amid Uncertainty and Strategic Exploration Hold Rating on SAGE Therapeutics Amid Underwhelming Sales and Strategic Uncertainties Sage Therapeutics price target lowered to $12 from $14 at H.C. Wainwright PremiumPre-EarningsSAGE Earnings Report this Week: Is It a Buy, Ahead of Earnings? Sage Therapeutics price target raised to $9 from $6 at Mizuho Sage Rejects Biogen Bid but Could be Open to Other Offers 
